ORIGINAL ARTICLES  ADVANCES IN RADIOIMMUNOIMAGING AND RADIOIMMUNOTHERAPY 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 December;51(4):352-6

Copyright © 2007 EDIZIONI MINERVA MEDICA

lingua: Inglese

Iodine-123-interleukin-2 scintigraphy in metastatic hypernephroma: a pilot study

Renard V. ¹, Staelens L. ², Signore A. ^{3, 4}, Van Belle S. ¹, Dierckx R. A. ⁴, Van De Wiele C. ⁵

¹ Department of Medical Oncology Ghent University Hospital, Ghent, Belgium 2 Department of Radiopharmacy University of Ghent, Ghent, Belgium 3 Department of Nuclear Medicine La Sapienza University of Rome, Rome, Italy 4 Department of Nuclear Medicine and Molecular Imaging Groningen University Medical Center University of Groningen, Groningen, The Netherlands 5 Department of Nuclear Medicine Ghent University Hospital, Ghent, Belgium

Aim. This pilot study reports on the uptake of 123I-interleukin 2 (IL-2) in metastatic renal cell carcinoma (MRCC) patients and its relationship to prognostic factors of response or failure of MRCC to cytokines treatment.
Methods. Nine consecutive patients with MRCC underwent an 123I-IL-2 scan (6 male and 3 female; mean age 64 years; range 51-78). Uptake in metastases was related to a summed score of 4 independent factors, predictive of rapid progression under cytokine treatment as defined by Negrier et al.
Results. Four patients presented with metastases at one site, 4 at 2 sites and one patient at 3 different sites. Summed scores were: 5 patients had a summed score of 1; 3 a summed score of 2 and 1 patient a summed score of 3. Uptake of 123I-IL-2 by tumor tissue was found in only 2 patients. Uptake occurred in 1 patient with a summed score of 3 and in 1 with a summed score of 2.
Conclusion. In this small series of patients with MRCC, 123I-IL-2 uptake was found in tumors of 2 patients who less likely will benefit from cytokine treatment. Additional studies are needed to assess the relationship between the pretreatment uptake of 123I-IL2 in MRCC and the response to IL-2 therapy.